

NOV 19 2002

K023698
page 1 of 2

9.0 510(k) Summary

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 C.F.R. §807.92.

1. The submitter of this premarket notification is:

Philips Medical Systems

This summary was prepared on 1 November, 2002.

2. The name of this device is the M3290A IntelliVue Information Center Software Release E.0 (for DataBase Server with Web Server including Near-Realtime Export). Classification names are as follows:

Classification	ProCode	Description
None	74 MHX	Physiological Monitor, Patient Monitor
870.1025, III	74 DSI	Arrhythmia Detector and Alarm
870.1025, III	74 MLD	Monitor, ST Alarm
870.2800, II	74 DSH	Recorder, Magnetic Tape, Medical
870.2300, II	74 MSX	System, Network and Communication, Physiological Monitors

3. The new device is substantially equivalent to the previously cleared VIC Web software cleared under K993907.

4. The modification is a software-based change that provides improved database server access via the hospital intra/internet system.

5. The new device has the same Indications for Use as the legally marketed predicate device. For central monitoring of multiple adult, pediatric, and neonatal patients; and where the clinician decides to monitor cardiac arrhythmia of adult, pediatric, and neonatal patients and/or ST segment of adult patients to gain information for treatment, to monitor adequacy of treatment, or to exclude causes of symptoms.

6. The new device has the same technological characteristics as the legally marketed predicate device.

7. Verification, validation, and testing activities establish the performance, functionality, and reliability characteristics of the new device with respect to the

predicate. Testing involved system level tests, integration tests, environmental tests, and safety testing from hazard analysis. Pass/Fail criteria were based on the specifications cleared for the predicate device and test results showed substantial equivalence. The results demonstrate that web software interface functionality meets all reliability requirements and performance claims.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

NOV 19 2002

Philips Medical Systems
c/o Mr. David Osborn
Quality Program Manager
3000 Minuteman Road
Andover, MA 01810

Re: K023698

Trade Name: M3290A IntelliVue DataBase Server Software for M3154 with Web Server
including Near-Realtime export, Release E.0

Regulation Number: 21 CFR 870.1025

Regulation Name: Patient Physiological Monitor (with arrhythmia detection and alarms)

Regulatory Class: Class III (three)

Product Code: MHX

Dated: November 1, 2002

Received: November 4, 2002

Dear Mr. Osborn:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Page 2 – Mr. David Osborn

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Bram D. Zuckerman". The signature is fluid and cursive, with a long horizontal stroke extending to the right.

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

510(k) Number (if known): _____

Device Name: M3290A IntelliVue DataBase Server Software for M3154
with Web Server including Near-Realtime export, Release E.0

Indications for Use: For central monitoring of multiple
adult, pediatric, and neonatal patients; and where the clinician
decides to monitor cardiac arrhythmia of adult, pediatric, and
neonatal patients and/or ST segment of adult patients to gain
information for treatment, to monitor adequacy of treatment, or
to exclude causes of symptoms.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒ OR Over-The-Counter Use
(Per 21 CFR 801.109)

(Optional Format 1-2-96)

Office of Cardiovascular & Respiratory Devices
Number K02-3698
DOE 11/18